Hepatoprotective Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, and Lycopene in Experimental Chronic Hepatitis Compared to Phosphogliv

A phytocomposition of soy lecithin, glycyrrhizic acid, lycopene, and ecdysterone (conventional name Hepalipin) significantly prevents the development of cytolytic-cholestatic liver damage, contributes to the maintenance of protein- and glycogen-synthesizing functions of the liver, reduces its fatty...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical chemistry journal 2023-02, Vol.56 (11), p.1433-1438
Main Authors: Syrov, V. N., Gusakova, S. D., Khushbaktova, Z. A., Egamova, F. R., Khidoyatova, Sh. K., Sagdullaev, Sh. Sh
Format: Article
Language:English
Subjects:
Amobarbital
Carbon tetrachloride
Glycogen
Hepatitis
Lecithin
Lipids
Lycopene
Medicine
Molecular-Biological Problems of Drug Design and Mechanism of Drug Action
Organic Chemistry
Pharmacology/Toxicology
Pharmacy
Physiological aspects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A phytocomposition of soy lecithin, glycyrrhizic acid, lycopene, and ecdysterone (conventional name Hepalipin) significantly prevents the development of cytolytic-cholestatic liver damage, contributes to the maintenance of protein- and glycogen-synthesizing functions of the liver, reduces its fatty degeneration, restrains disorders of pigment metabolism, and exhibits an antioxidant effect when administered to experimental animals against the background of developing chronic toxic hepatitis caused by carbon tetrachloride. Hepalipin improves disturbed bile chemical composition and secretion. The continued administration of Hepalipin to rats for another two weeks after the cessation of carbon tetrachloride injections leads to almost complete restoration of all studied parameters to their initial (intact) values. Hepalipin under conditions of experimental chronic hepatitis showed statistically significant advantages compared to Phosphogliv in terms of the intensity of the hepatoprotective effect.
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-023-02811-6